Back to top
more

Syros Pharmaceuticals (SYRS)

(Real Time Quote from BATS)

$4.90 USD

4.90
24,488

-0.10 (-2.00%)

Updated May 29, 2024 11:02 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SYRS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Syros Pharmaceuticals, Inc. [SYRS]

Reports for Purchase

Showing records 201 - 220 ( 221 total )

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 201

10/23/2017

Company Report

Pages: 16

"Festina Lente"; Initiating with Neutral and $15 PT

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 202

10/23/2017

Industry Report

Pages: 13

The Brave New World of AML

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 203

09/12/2017

Industry Report

Pages: 6

Biotechnology -ESMO 2017 Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 204

08/31/2017

Industry Report

Pages: 7

Biotechnology - ESMO ''17 Abstract Roundup and Schedule for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 205

08/25/2017

Industry Report

Pages: 7

HEALTHCARE - Corrected: The Week Ahead

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 206

08/25/2017

Industry Report

Pages: 7

HEALTHCARE - The Week Ahead

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 207

08/18/2017

Industry Report

Pages: 7

HEALTHCARE - The Week Ahead

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 208

08/10/2017

Company Report

Pages: 7

2Q, Ticking PT to $25 as Ph 2 SY-1425 Readout Nears

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 209

08/10/2017

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 210

06/19/2017

Daily Note

Pages: 4

KOL Feedback on Tamibarotene in AML is Cautious; Reit Neutral - $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 211

05/19/2017

Industry Report

Pages: 6

EHA Abstract Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 212

05/16/2017

Company Report

Pages: 5

1Q, Ph 2 SY-1425 Data Next Half Could Establish Proof-of- Concept in Multiple AML/MDS Subpopulations, Reiterate OP

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 213

04/12/2017

Industry Report

Pages: 6

AACR 2017 Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 214

03/20/2017

Company Report

Pages: 7

4Q/FY16, SYRS Looks Attractive with Major Pipeline Catalysts This Year, Reiterate OUTPERFORM and Increasing PT to $22

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 215

12/07/2016

Company Report

Pages: 6

Too Much Retinoid May Not Be a Good Thing

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 216

12/06/2016

Industry Report

Pages: 9

Additional ASH Updates for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 217

11/28/2016

Industry Report

Pages: 10

ASH 2016: Additional Abstracts and Sessions of Interest

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 218

11/14/2016

Company Report

Pages: 6

3Q, Well Capitalized to Advance Pipeline Forward, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 219

08/15/2016

Company Report

Pages: 7

2Q, SY-1425 Ph 2 Study Enrollment Initiated, Reiterate OP

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Unclassified

Record: 220

07/22/2016

Company Report

Pages: 25

Initiating Coverage with an OUTPERFORM Rating - $18 PT; A New Frontier in Gene Regulation

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party